BRPI0911482A2 - Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer - Google Patents

Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer

Info

Publication number
BRPI0911482A2
BRPI0911482A2 BRPI0911482A BRPI0911482A BRPI0911482A2 BR PI0911482 A2 BRPI0911482 A2 BR PI0911482A2 BR PI0911482 A BRPI0911482 A BR PI0911482A BR PI0911482 A BRPI0911482 A BR PI0911482A BR PI0911482 A2 BRPI0911482 A2 BR PI0911482A2
Authority
BR
Brazil
Prior art keywords
treatment
tau
including alzheimer
epothylone
associated diseases
Prior art date
Application number
BRPI0911482A
Other languages
English (en)
Inventor
F Albright Charles
Marie Barten Donna
Y Lee Francis
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40887113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911482(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0911482A2 publication Critical patent/BRPI0911482A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE EPOTILONA D NO TRATAMENTO DE DOENÇAS ASSOCIADAS A TAU INCLUINDO DOENÇA DE ALZHEIMER. A presente invenção refere-se a métodos de tratamento de doenças associadas a Tau, preferivelmente tauopatias, são descritos usandose epotilona D que exibe boa penetração no cérebro, longa meia-vida, e alta retenção seletiva no cérebro, e proporciona terapias efetivas no tratamento de tauopatias incluindo doença de Alzheimer.
BRPI0911482A 2008-04-24 2009-04-24 Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer BRPI0911482A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4772908P 2008-04-24 2008-04-24
PCT/US2009/041634 WO2009132253A1 (en) 2008-04-24 2009-04-24 Use of epothelone d in treating tau-associated diseases including alzheimer's disease

Publications (1)

Publication Number Publication Date
BRPI0911482A2 true BRPI0911482A2 (pt) 2017-08-29

Family

ID=40887113

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911482A BRPI0911482A2 (pt) 2008-04-24 2009-04-24 Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer

Country Status (25)

Country Link
US (3) US20090270465A1 (pt)
EP (1) EP2276485B1 (pt)
JP (1) JP5548675B2 (pt)
KR (1) KR20100137576A (pt)
CN (3) CN104666297A (pt)
AR (1) AR071598A1 (pt)
AU (1) AU2009240538B2 (pt)
BR (1) BRPI0911482A2 (pt)
CA (1) CA2722371C (pt)
CL (1) CL2009000990A1 (pt)
CY (1) CY1115617T1 (pt)
DK (1) DK2276485T3 (pt)
EA (1) EA021758B1 (pt)
ES (1) ES2501565T3 (pt)
HR (1) HRP20140783T1 (pt)
HU (1) HUE024506T2 (pt)
IL (1) IL208926A0 (pt)
MX (1) MX2010011209A (pt)
NZ (1) NZ588555A (pt)
PL (1) PL2276485T3 (pt)
PT (1) PT2276485E (pt)
SI (1) SI2276485T1 (pt)
TW (1) TWI472329B (pt)
WO (1) WO2009132253A1 (pt)
ZA (1) ZA201007460B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7776905B2 (en) 2006-04-07 2010-08-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2155197A4 (en) * 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
NZ588555A (en) 2008-04-24 2012-06-29 Bristol Myers Squibb Co Use of epothilone d in treating tau-associated diseases including alzheimer's disease
US20100160372A1 (en) * 2008-11-13 2010-06-24 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
MX2011005096A (es) 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
US8563593B2 (en) * 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
HK1204970A1 (en) * 2012-01-31 2015-12-11 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP6321521B2 (ja) * 2014-11-04 2018-05-09 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 タウ蛋白産生促進剤、タウ蛋白の欠乏に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物
CA3028035A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
JP7536098B2 (ja) * 2020-09-02 2024-08-19 北京華昊中天生物医薬股▲ふん▼有限公司 ウチデロンの経口固形製剤
CN113005086B (zh) * 2021-02-01 2022-10-28 中国科学院遗传与发育生物学研究所 埃博霉素D和Apol8在调控神经干细胞定向神经元分化中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5580898A (en) * 1994-05-24 1996-12-03 The Trustees Of The University Of Pennsylvania Method of stabilizing microtubules
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6320045B1 (en) * 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
AU738576B2 (en) * 1997-12-04 2001-09-20 Bristol-Myers Squibb Company A process for the reduction of oxiranyl epothilones to olefinic epothilones
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
WO2000007151A1 (de) 1998-07-27 2000-02-10 Siemens Aktiengesellschaft Sicherheitspapier sowie verfahren und vorrichtung zur prüfung der echtheit darauf aufgezeichneter urkunden
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
WO2000050423A1 (en) * 1999-02-22 2000-08-31 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modified epothilones
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
EP1303615A2 (en) 2000-07-25 2003-04-23 Kosan Biosciences, Inc. Fermentation process for epothilones
JP3604337B2 (ja) * 2000-10-03 2004-12-22 古河電気工業株式会社 絶縁電線の製造方法
ATE349412T1 (de) 2000-10-16 2007-01-15 R & D Biopharmaceuticals Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten
TW476749B (en) * 2000-11-17 2002-02-21 Nat Science Council Process for preparing 2,6-dimethylphenol
FR2817117B1 (fr) 2000-11-24 2005-11-04 Commissariat Energie Atomique Mammiferes non-humains transgeniques ou recombinants et leurs applications dans le criblage de medicaments utiles dans les desordres psychoactifs
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
CA2436735A1 (en) * 2001-02-02 2002-08-15 The Regents Of The University Of California Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
WO2002098868A1 (en) * 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Epothilone derivatives
US7220560B2 (en) 2002-02-25 2007-05-22 Kosan Biosciences Incorporated Secondary metabolite congener distribution modulation
US7082674B2 (en) * 2002-02-27 2006-08-01 Sumitomo Heavy Industries, Ltd. Method for winding a single coil of a coil unit for a linear motor
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
DK1483251T3 (da) * 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
DK1521752T3 (da) 2002-07-15 2009-06-22 Helmholtz Infektionsforschung Makrocykliske forbindelser til behandling af cancer
AU2003260723A1 (en) 2002-08-17 2004-03-03 The Queens Universlty Of Belfast Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
KR20050053681A (ko) 2002-09-23 2005-06-08 브리스톨-마이어스 스큅 컴퍼니 에포틸론 ｂ의 제조, 분리 및 정제 방법, 및 에포틸론 ｂ의ｘ-선 결정 구조
EP1608626A1 (en) * 2003-03-28 2005-12-28 Cornell Research Foundation, Inc. Migrastatin analog compositions and uses thereof
US6954131B2 (en) * 2003-04-02 2005-10-11 Illinois Tool Works Inc. Electrical reactor assembly having center taps
CN1867343A (zh) * 2003-10-09 2006-11-22 高山生物科学股份有限公司 治疗制剂
EP1559447A1 (en) * 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
EP1818016B1 (en) 2004-07-20 2019-02-20 Toshinori Kato Biofunction diagnosis device, biofunction diagnosis method, bioprobe, bioprobe wearing tool, bioprobe support tool, and bioprobe wearing assisting tool
US20060142393A1 (en) * 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
AU2007288340A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
AU2007288339B2 (en) * 2006-08-21 2011-08-18 Synta Pharmaceuticals Corp. Compounds for treatment of proliferative disorders
US8609720B2 (en) * 2006-08-21 2013-12-17 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
NZ588555A (en) 2008-04-24 2012-06-29 Bristol Myers Squibb Co Use of epothilone d in treating tau-associated diseases including alzheimer's disease

Also Published As

Publication number Publication date
CY1115617T1 (el) 2017-01-04
WO2009132253A1 (en) 2009-10-29
PT2276485E (pt) 2014-10-20
KR20100137576A (ko) 2010-12-30
TWI472329B (zh) 2015-02-11
EP2276485A1 (en) 2011-01-26
HUE024506T2 (en) 2016-01-28
CL2009000990A1 (es) 2010-10-15
AR071598A1 (es) 2010-06-30
AU2009240538B2 (en) 2014-08-07
US8673949B2 (en) 2014-03-18
AU2009240538A1 (en) 2009-10-29
US20140135367A1 (en) 2014-05-15
NZ588555A (en) 2012-06-29
TW200948360A (en) 2009-12-01
ZA201007460B (en) 2012-03-28
HK1153152A1 (en) 2012-03-23
EA201001695A1 (ru) 2011-08-30
ES2501565T3 (es) 2014-10-02
PL2276485T3 (pl) 2014-12-31
CN102076339A (zh) 2011-05-25
US20110230528A1 (en) 2011-09-22
US20090270465A1 (en) 2009-10-29
CN104666297A (zh) 2015-06-03
EP2276485B1 (en) 2014-07-16
CA2722371C (en) 2016-06-21
HRP20140783T1 (hr) 2014-09-12
JP5548675B2 (ja) 2014-07-16
DK2276485T3 (da) 2014-10-13
SI2276485T1 (sl) 2014-10-30
CN104116736A (zh) 2014-10-29
MX2010011209A (es) 2010-11-12
IL208926A0 (en) 2011-01-31
EA021758B1 (ru) 2015-08-31
JP2011522782A (ja) 2011-08-04
CA2722371A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
PT2529621T (pt) Inibidores de tirosina cinase de bruton
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
BRPI0607002A2 (pt) aptámeros terapêuticos úteis no tratamento de desordens relacionadas a complemento
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
BR112013008140A2 (pt) "compostos imidazotriazinona".
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
BRPI0606108A2 (pt) processo de tratamento
MX385354B (es) Sales de xantilio 3,6-disustituidas.
EP3558340A4 (en) METHOD FOR USE OF GM6 IN DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
WO2010041252A3 (en) Use of a cinnamon bark extract for treating amyloid-associated diseases
WO2007035474A3 (en) Transdermal delivery peptides and method of use thereof
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
ATE439443T1 (de) NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
WO2006109301A3 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]